Sedentary Behaviour, Physical Activity Patterns, and Cardiometabolic Health
SPARC
From Sitting to Moving: How Physical Activity Patterns Can Reduce Sedentary Behaviour and Support Cardiometabolic Health
1 other identifier
interventional
48
1 country
1
Brief Summary
According to the World Health Organization (WHO), chronic diseases are a major global public health concern and the leading cause of mortality worldwide. In the absence of evidence-based actions, the global annual deaths from chronic diseases are projected to rise to 55 million deaths in 2030, accompanied by a substantial increase in socio-economic costs. In this context, the WHO identifies type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD) as key chronic conditions of concern related to cardiometabolic health. Both sedentary behaviour (SB) and physical inactivity have been recognised as interdependent risk factors for the development of T2DM and CVD. SB refers to any waking behaviour, characterised by a low energy expenditure, while being in a sitting or reclining posture, whereas physical inactivity denotes insufficient levels (\<150 min per week,) of moderate-to-vigorous physical activity (MVPA). Studies using objective measures have demonstrated that on average Western adults spend 8-12h in SB per day, of which the majority is spent in prolonged sedentary bouts (lasting ≥30 min). In addition, up to 30% of adults worldwide are physically inactive, with higher levels of inactivity in high-income countries. Within this context, it has become evident that excessive prolonged SB, often in combination with physical inactivity, negatively impacts cardiometabolic health, contributing to insulin resistance, increased adiposity, poor lipid profiles and endothelial dysfunction. Given their detrimental effects on T2DM and CVD, strategies aimed at reducing SB and promoting physical activity (PA) warrant further investigation. Reducing and regularly interrupting SB, even with low-intensity PA, alongside sufficient MVPA, is crucial for maintaining a healthy cardiometabolic profile. Reflecting this, the WHO guidelines advise individuals to engage in 150-300 minutes of moderate-intensity physical activity, 75-150 minutes of vigorous-intensity physical activity, or an equivalent combination each week. Notably, the 2020 WHO guidelines also included recommendations on SB for the first time, emphasizing the importance of limiting sedentary time. The WHO states that replacing SB with physical activity of any intensity can yield health benefits. However, these recommendations remain non-prescriptive and somewhat vague, primarily due to a lack of robust scientific evidence on the optimal frequency, intensity, and duration of PA needed to interrupt sedentary time. The absence of specific guidelines on prolonged SB reflects this evidence gap. To support policy development, well-designed randomised controlled trials are needed to evaluate effective and practical strategies for reducing sedentary time. So far, the short term cardiometabolic health effects of SB interruptions have been investigated by our research group, laboratory studies of collaborators and other international researchers, demonstrating that; 1) more frequent SB interruptions especially affect glucose metabolism and insulin sensitivity; 2) higher intensity interruptions are associated with cardioprotective adaptations and; 3) longer durations of SB interruptions positively affect lipid metabolism. However, because under real-world conditions frequency, intensity and duration of SB interruptions usually interact, their combined effects on cardiometabolic health need further investigation. Many studies already compared the isolated effects of different SB interruption patterns with respect to frequency, duration and intensity on cardiometabolic health. However, the combined effects of these different approaches matched for energy expenditure are not clear yet. We therefore perform a balanced cross-over study in which the efficacy of distinct activity patterns on cardiometabolic health insulin sensitivity and vascular function) will be compared to a sedentary control condition.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Mar 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 3, 2026
CompletedFirst Posted
Study publicly available on registry
February 18, 2026
CompletedStudy Start
First participant enrolled
March 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2028
February 18, 2026
February 1, 2026
2.3 years
February 3, 2026
February 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Total and incremental area under the curve of postprandial insulin response
Insulin concentrations will be assessed in serum samples at nine time points over the 6-hour testing period. Postprandial responses will be quantified as the area under the curve (AUC) across the six-hour period.
Blood samples will be collected at 0, 30, 60, 120, 180, 210, 240, 300, and 360 minutes during the 6-hour testing day.
Vascular endothelial function
Vascular endothelial function will be assessed by flow-mediated dilation (FMD) according to published guidelines. These measurements take place at 8 a.m. and involve doppler ultrasound imaging of the superficial femoral artery. A cuff will be placed on the right lower leg, and the superficial femoral artery is imaged longitudinally. FMD will be measured at baseline and after a 5-min occlusion phase (reactive hyperaemia response). FMD will be quantified as the percentage difference between peak and baseline diameter (FMD%).
FMD measurement will be performed at the start (08:30 a.m.) and after 6 hours (2:30 p.m.) of the testing day.
Secondary Outcomes (14)
Cardiorespiratory Fitness
Baseline measurement
Sedentary time
Measured for 7 consecutive days after the screening visit
Body mass index
Baseline measurement
Moderate-to-vigorous physical activity
Measured for 7 consecutive days after the screening visit
Body weight
Baseline measurement
- +9 more secondary outcomes
Study Arms (6)
Control
NO INTERVENTIONProlonged sitting for 6 hours
Continuous moderate intensity physical activity
EXPERIMENTALOne continuous physical activity bout of moderate intensity will be performed during the 6 hour testing day.
Continuous moderate intensity physical activity + light-intensity physical activity breaks
EXPERIMENTALOne continuous physical activity bout of moderate intensity will be combined with light-intensity physical activity breaks every 30 minutes during the 6 hour testing day.
Continuous moderate intensity physical activity + high-intensity physical activity breaks
EXPERIMENTALOne continuous physical activity bout of moderate intensity will be combined with high-intensity physical activity breaks every 30 minutes during the 6 hour testing day.
Light-intensity physical activity breaks
EXPERIMENTALProlonged sitting will be interrupted by light-intensity physical activity breaks every 30 minutes during the 6-hour testing day.
High-intensity physical activity breaks
EXPERIMENTALProlonged sitting will be interrupted by high-intensity physical activity breaks every 30 minutes during the 6-hour testing day.
Interventions
One continuous physical activity bout of moderate intensity will be performed during the 6 hour testing day.
Light-intensity physical activity breaks every 30 minutes during the 6 hour testing day.
High-intensity physical activity breaks every 30 minutes during the 6 hour testing day.
Eligibility Criteria
You may qualify if:
- Adults aged 40-70 years
- Sedentary (\>9 hours per day)
- \< 3 exercise sessions per week
You may not qualify if:
- Pregnancy or intend to become pregnant
- Any known contra-indications for physical activity
- \>14 alcohol consumptions per week for women and \>20 alcohol consumptions per week for men
- Involved in a weight reduction program with an energy restriction diet during the study period
- No consistent body weight over the past month
- Diagnosed with any known cardiometabolic health-related disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hasselt University
Diepenbeek, Limburg, 3590, Belgium
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
February 3, 2026
First Posted
February 18, 2026
Study Start
March 1, 2026
Primary Completion (Estimated)
June 1, 2028
Study Completion (Estimated)
June 1, 2028
Last Updated
February 18, 2026
Record last verified: 2026-02